1Pozzilli P, Visalli N, Signore A, Baroni MG, Buzzetti R, Cavallo MG, et al. Double-blind trial of nicotinamide in recent-onset insulin-dependent diabetes mellitus. Diabetologia 1995; 38: 848-52.
2Pozzilli P, Browne PD, Kolb H. Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. The Nicotinamide Trialists. Diabetes Care 1996, 19: 1357-63.
3Pozzilli P, Visalli N, Buzzetti R, Cavallo MG, Marietti G, Hawa M, et al. Metabolic and immune parameters at clinical onset of insulin-dependent diabetes: a population based study. Metabolism 1998; 47:1205-10.
4Lampeter EE Klinghammer A, Scherbaum WA, Heinze E, Haastert B, Giant G, et al. The Deutsche nicotinamide intervention study:an attempt to prevent type 1 diabetes. Diabetes 1998; 47: 980-4.
5Pozzilli P, Maclaren NK. Immunotherapy at clinical diagnosis of insulin dependent diabetes. Trends Endocrinol Metab 1993;4: 101-5.
6Crino A, Schiaffini R, Manfrini S, Visalli N, Anguissola GB,Pitocco D, et al. A randomized trial of nicotinamide and vitamin E in children with recent onset type one diabetes (IMDIAB 1X).Eur J Endocrinol 2004; 150: 719-24.
7Pozzilli E Visalli N, Cavallo MG, Signore A, Baroni MG, Buzzetti R, et al. Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulindependant diabetes (the IMDIAB 1V study). Eur J Endocrinol 1997; 137: 234-9.
8Kallamann B, Burkart V, Kroncke KD, Kolb-Baclofen V, Kolb H.Toxicity of chemically generated nitric oxide towards pancreatic islet cell can be prevented by nicotinamide. Life Sci 1992; 51:671-8.
10Bowman MA, Leiter EH, Atkinson MA. Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease. Immunol Today 1994; 15: 115-20.
2Miyata T, Yamada N, Miyachi Y. Efficacy by ulcer type and safety of lipo-PGE1 for Japanese patients with diabetic foot ulcers[J]. J Atheroscler Thromb, 2010, 17(8):805-816.
3Piaggesi A, Abbruzzese L, Mattaliano C, et al. Sulodexide as adjunctive therapy in diabetic foot patients with critical limb ischemia treated with percutaneous transluminal angioplasty [J]. IntLow Ext.rem Wounds, 2014,13(2).:103-109-.
4Ciccone MM, Marchses A, Generali A, et al. Interventional therapy in diabetic foot: risk factors, clinical events and prognosis at one year follow-up (a study of 103 cases)[J]. Pak J Biol Sci, 2012, 15(16):789-794.
5Gonzalez-Vicent M, Herrero B, Guillen M, et al. Using Rheopheresis for stem cell Transplantation-Associated Thrombotic Microangiopathy (TA-TMA)[J]. Transfus Apher Sci, 2013, 49(2):234-237.
6Zheng XT, Zeng RC, Huang JY, et al.The use of the angiosome concept for treating infrapopliteal critical limb ischemia through interventional therapy and determining the clinical significance of collateral vessels [J]. Ann Vasc Surg, 2016(32):41-49.
